These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 18366985)

  • 1. Pleiotropic effects: should statins be considered an essential component in the treatment of dyslipidemia?
    Mays ME; Dujovne CA
    Curr Atheroscler Rep; 2008 Feb; 10(1):45-52. PubMed ID: 18366985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleiotropic effects of statins: do they matter?
    Gotto AM; Farmer JA
    Curr Opin Lipidol; 2001 Aug; 12(4):391-4. PubMed ID: 11507323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM; Farmer JA
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging views of statin pleiotropy and cholesterol lowering.
    Yu D; Liao JK
    Cardiovasc Res; 2022 Jan; 118(2):413-423. PubMed ID: 33533892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel concepts of statin therapy for cardiovascular risk reduction in hypertension.
    Varughese GI; Patel JV; Lip GY; Varma C
    Curr Pharm Des; 2006; 12(13):1593-609. PubMed ID: 16729872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.
    Marzilli M
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():3-9. PubMed ID: 21391728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality.
    Lim S; Sakuma I; Quon MJ; Koh KK
    Int J Cardiol; 2013 Sep; 167(5):1696-702. PubMed ID: 23159411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMG-CoA reductase inhibitors and the kidney.
    Campese VM; Park J
    Kidney Int; 2007 Jun; 71(12):1215-22. PubMed ID: 17495867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
    Ray KK; Cannon CP; Ganz P
    Am J Cardiol; 2006 Dec; 98(11A):18P-25P. PubMed ID: 17126675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMG-CoA reductase inhibitors and the kidney.
    Campese VM; Hadaya B; Chiu J
    Curr Hypertens Rep; 2005 Oct; 7(5):337-42. PubMed ID: 16157074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive interventions in myocardial infarction: the role of statin therapy.
    Jones PH; Farmer JA
    Curr Atheroscler Rep; 2008 Apr; 10(2):142-8. PubMed ID: 18417069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropic effects of pitavastatin.
    Davignon J
    Br J Clin Pharmacol; 2012 Apr; 73(4):518-35. PubMed ID: 22053916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleiotropic effects of statins: moving beyond cholesterol control.
    Garcia PJ
    Curr Atheroscler Rep; 2005 Feb; 7(1):34-9. PubMed ID: 15683600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Dana T; Blazina I; Daeges M; Jeanne TL
    JAMA; 2016 Nov; 316(19):2008-2024. PubMed ID: 27838722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.